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Abstract 1 
Objectives: This study investigated the influence of a moderate caffeine dose on endurance cycle 2 
performance and thermoregulation during prolonged exercise in high ambient temperature.  3 
Design: Double-blind cross-over study. 4 
Methods: Eight healthy, recreationally active males (Mean ± SD; age: 22 ± 1 y; body mass: 71.1 ± 8.5 5 
kg; VO2peak: 55.9 ± 5.8 mL·kg−1·min−1; Wmax: 318 ± 37 W) completed one VO2peak test, one 6 
familiarisation trial and two experimental trials. After an overnight fast, participants ingested a 7 
placebo or a 6 mg·kg−1 caffeine dose 60 min before exercise. The exercise protocol consisted of 60 8 
min of cycle exercise at 55% Wmax, followed by a 30 min performance task (total kJ produced) in 9 
30oC and 50% RH. 10 
Results: Performance was enhanced (Cohen’s d effect size=0.22) in the caffeine trial (363.8 ± 47.6 kJ) 11 
compared with placebo (353.0 ± 49.0 kJ; p=0.004). Caffeine did not influence core (p=0.188) or skin 12 
temperature (p=0.577) during exercise. Circulating prolactin (p=0.572), cortisol (p=0.842) and the 13 
estimated rates of fat (p=0.722) and carbohydrate oxidation (p=0.454) were also similar between trial 14 
conditions. Caffeine attenuated perceived exertion during the initial 60 min of exercise (p=0.033), 15 
with no difference in thermal stress across trials (p=0.911). 16 
Conclusions: Supplementation with 6 mg·kg−1 caffeine improved endurance cycle performance in a 17 
warm environment, without differentially influencing thermoregulation during prolonged exercise at a 18 
fixed work-rate versus placebo. Therefore, moderate caffeine doses which typically enhance 19 
performance in temperate environmental conditions also appear to benefit endurance performance in 20 
the heat.  21 
 22 
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Introduction 25 
Caffeine (1,3,7-trimethylxanthine) is a well-established ergogenic aid commonly consumed by 26 
endurance athletes.1 Intakes of low to moderate doses (3-6 mg·kg−1) consistently enhance performance 27 
in temperate environmental conditions (~20oC), especially when exercise is performed for 30 min or 28 
longer.2 Few studies have investigated the ergogenic effects of caffeine in the heat, with some,3,4 but 29 
not all,5, 6, 7 reporting improved performance following caffeine ingestion. Hence, from the limited 30 
data available, it is unclear whether caffeine benefits endurance performance in the heat, despite a 31 
high prevalence of intake among athletes competing in warm environments1.  32 
The progressive impairment in endurance capacity with increasing ambient temperature is well-33 
documented.8 Several explanations for this deterioration in performance have been proposed, 34 
including an increased physiological burden to dissipate heat via the skin and an elevated core 35 
temperature9. The resulting hyperthermia and increased brain temperature reduce central drive to 36 
continue exercise, thus precipitating the onset of fatigue.10 During prolonged exercise in the heat, 37 
caffeine has elicited higher core temperatures than placebo.5,6,11 Therefore, these perturbations to 38 
thermoregulation might explain the lack of performance benefit in the heat after caffeine intake.5 39 
Interestingly, larger caffeine doses (≥ 9 mg·kg−1) consistently induce elevations in core and body 40 
temperature during exercise in the heat.6,11 Hence, the provision of smaller doses (~6 mg·kg−1), which 41 
typically improve performance in temperate conditions,2 might prove a more useful strategy to 42 
enhance performance in the heat.  43 
Supplementation with 6 mg·kg−1 caffeine enhanced maximal voluntary contraction of the quadriceps 44 
after prolonged cycle exercise in a hot (36oC) environment.4 However, during exercise under the same 45 
environmental conditions, the same caffeine dose co-administered with carbohydrates elicited a 46 
higher core temperature than isolated carbohydrate intake.12 To date, only two laboratory-based 47 
studies have examined the influence of 6 mg·kg−1 caffeine on endurance cycle performance in the heat 48 
without additional carbohydrates.5,3 Roelands et al. (2011)5 reported no ergogenic effect of caffeine 49 
but an increase in core temperature during prolonged exercise at a fixed work-rate, while Ganio et al. 50 
4 
 
(2011)3 observed an improvement in endurance cycle performance but no thermogenic effects. Hence, 51 
it is unclear whether moderate caffeine doses influence endurance cycle performance or 52 
thermoregulation during prolonged exercise in the heat. Given the widespread intake of caffeine by 53 
athletes,1 it would be of interest to determine whether moderate doses which consistently enhance 54 
performance in temperate conditions,2 also confer performance benefits in the heat. 55 
Consequently, the aim of this study was to examine the performance and thermoregulatory responses 56 
to prolonged exercise in the heat following the ingestion of a 6 mg·kg−1 caffeine dose versus a placebo 57 
condition.  58 
 59 
Methods 60 
Eight healthy, recreationally active, low-caffeine consuming, non-heat acclimated males (116 ± 46 61 
mg·day−1; age: 22 ± 1 y; body mass: 71.1 ± 8.5 kg; height: 1.74 ± 0.08 m; VO2peak: 55.9 ± 5.8 62 
mL·kg−1·min−1; peak power output at VO2peak [Wmax]: 318 ± 37 W) took part in this investigation, 63 
which employed a double-blind, randomised, repeated-measures, cross-over design. Participants 64 
provided written informed consent and were free from chronic disease. The experimental protocol 65 
was approved by the Ethics Approvals (Human Participants) Sub-Committee of Loughborough 66 
University, UK (Ref: R15-P104). 67 
All participants completed one maximal exercise test, one familiarisation trial and two experimental 68 
trials. The initial visit consisted of an incremental exercise test to volitional exhaustion conducted on 69 
an electronically braked cycle ergometer (Lode Corival, Groningen, Holland) to determine Wmax and 70 
the power required to elicit 55% and 75% of Wmax. This test was performed in temperate conditions 71 
(~20oC). After a brief recovery period (15 min), participants completed the performance task used in 72 
the familiarisation and experimental trials to practice pacing and control of the ergometer. After 5-7 73 
days, the familiarisation trial was undertaken to ensure that participants became fully accustomed to 74 
the procedures employed during the investigation and to minimise any learning or anxiety effects. 75 
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This trial was performed in environmental conditions maintained at 30oC and 50% RH and was 76 
identical to the experimental trials in all respects, although no treatment was administered.  77 
The familiarisation and experimental trials were separated by 7 to 10 days to minimise the 78 
development of heat acclimation. Additionally, all trials were performed at the same time of day to 79 
minimise circadian-type variance. Participants were instructed to record their dietary habits and 80 
physical activity patterns during the 24 hours before the familiarisation trial and to replicate this in the 81 
24 hours preceding each experimental trial. Furthermore, no strenuous exercise or caffeine intake was 82 
permitted during this period and participants were provided with a list of commonly consumed 83 
caffeinated foods and drinks to help achieve this. On the evening before each trial, participants 84 
ingested a radio-telemetry pill (CoreTemp, HQ Inc, Palmetto, Florida, USA) to enable the 85 
measurement of core temperature.  86 
Participants arrived at the laboratory in the morning (8-9 am) after an overnight fast (10-12 hours) 87 
with the exception of ingesting 500 mL of plain water approximately 90 min before arrival. Post-void 88 
nude body mass was recorded upon arrival (Adam AFW-120, Milton Keynes, UK) and a heart rate 89 
telemetry band (Polar Beat, Kempele, Finland) was positioned. Skin surface thermistors (Grant 90 
Squirrel SQ800, Cambridgeshire, UK) were attached to four sites (chest, upper arm, thigh and calf) 91 
for the determination of weighted mean skin temperature.13 Next, an indwelling 21 g cannula was 92 
inserted into an antecubital vein to enable repeated blood sampling; this was flushed with a small 93 
volume of saline after each sample to ensure patency. After 15 min of seated rest at room temperature 94 
(20oC), a baseline 7 mL venous sample was collected, following which participants ingested a capsule 95 
containing either 6 mg·kg−1 of caffeine (Sigma-Aldrich, UK) or 250 mg of starch (placebo; BDH Ltd, 96 
Poole, UK) with 50 mL of plain water. All capsules were indistinguishable with regards to dimension, 97 
weight and colour. Participants then remained seated for a further 60 min at room temperature. After 98 
45 min, core and skin temperature and heart rate were recorded at 5 min intervals, with a second 7 mL 99 
venous sample collected at 60 min.  100 
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Participants then entered the climatic chamber (Weiss-Gallenkamp, UK) maintained at 30oC and 50% 101 
RH and began 60 min of cycle exercise at a workload corresponding to 55% Wmax. During this period, 102 
core and skin temperature and heart rate were recorded every 5 min. Rating of perceived exertion 103 
(RPE)14 and perceived thermal stress (using a 21 point scale ranging from -10, unbearable cold, to +10, 104 
unbearable heat) were recorded every 10 min. Expired gas samples (1 min) were collected every 30 105 
min using the Douglas bag method; these values were used to determine the rates of substrate 106 
oxidation during exercise.15 Participants were provided with 150 mL of plain water (temperature: 20oC) 107 
every 15 min and a third 7 mL venous sample was collected at 60 min while participants remained 108 
seated on the ergometer. 109 
Subsequently, there was a 2-3 min delay while the ergometer was programmed for the performance 110 
task. Participants were instructed to produce as much work (kJ) as possible within 30 min; this 111 
method is consistent with previous studies.6,3 Before starting, all participants were encouraged to 112 
produce a maximal effort. The initial workload was set at 75% Wmax, but participants were free to 113 
adjust their power output as desired from the outset. During this period, participants received 114 
information regarding time elapsed and cadence, but no other information or verbal encouragement 115 
was provided. Core and skin temperature and heart rate were recorded every 5 min. A final 7 mL 116 
venous sample was collected immediately after the performance task while participants remained 117 
seated on the ergometer. The cannula, telemetry band and skin thermistors were then removed and 118 
after a short rest period, nude body mass was recorded after participants towelled dry. The change in 119 
body mass, corrected for fluid intake, was used to estimate sweat rate.   120 
All venous samples were collected into dry syringes. A small volume (2 mL) was dispensed into tubes 121 
containing K2EDTA and duplicate 100 μL sub-samples were deproteinised in 0.3 M perchloric acid. 122 
These were centrifuged, and the resulting supernatant was used to determine plasma glucose 123 
concentrations using a commercially available assay (GOD-PAP, Randox Ltd, UK). Haemoglobin 124 
(cyanmethemoglobin method) and haematocrit (microcentrifugation) values were used to estimate 125 
percentage changes to blood and plasma volumes relative to the baseline sample.16 The remaining 5 126 
mL was dispensed into tubes containing clotting activator and left for approximately 1 hour prior to 127 
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centrifugation at 1750 g for 10 min at 4oC. The resulting serum was stored at -21oC for the subsequent 128 
determination of cortisol and prolactin with ELISA (DRG diagnostic, Germany) and caffeine with 129 
reverse-phase HPLC.17  130 
All data were analysed using IBM SPSS statistics version 22.0. Normality of distribution was 131 
determined using the Shapiro-Wilk test. Exercise performance, pre-exercise body mass, initial core 132 
temperature, fasting plasma glucose, and estimated sweat rates were examined using a paired t-test. 133 
Cohen’s d effect size (ES) for differences in total work produced during the performance task was 134 
determined ([mean 1 - mean 2]/pooled SD) and interpreted as trivial (0-0.19), small (0.2-0.49), 135 
medium (0.5-0.79) or large (≥0.8) as described.18 Variables measured throughout each trial were 136 
examined with a two-way (trial x time) repeated-measures ANOVA. The Greenhouse-Geisser 137 
correction was applied where the assumption of sphericity had been violated. Where a significant 138 
main effect or interaction was identified, Bonferroni adjusted paired t-tests for normally distributed 139 
data or Bonferroni adjusted Wilcoxon Signed Rank tests for non-normally distributed data were used. 140 
Data are presented as mean ± SD throughout. Statistical significance was accepted at p<0.05.  141 
 142 
Results 143 
Pre-exercise body mass (p=0.732), initial core temperature (p=0.279) and fasting plasma glucose 144 
(p=0.454) were not different between trials, suggesting that participants began each trial in a similar 145 
physiological state.  146 
All eight participants completed both trials, no adverse effects were reported. There was a small 147 
increase (ES=0.22) in total work produced during the caffeine trial (363.8 ± 47.6 kJ) than placebo 148 
(353.0 ± 49.0 kJ; p=0.004). This represents a percentage increase in performance of 3.2 ± 2.4% (range: 149 
-0.4 to 7.7%; Figure 1). Post-study questionnaires revealed that three of the eight participants (37.5%) 150 
correctly identified the caffeine trial, thus blinding can be considered successful as these odds are less 151 
than what would be expected purely by chance. 152 
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Pre-exercise core temperature was similar between trials (p=0.718; Figure 2A). There was a main 153 
effect of time during the initial 60 min of exercise (p<0.05), but no main effect of trial (p=0.188) or 154 
trial x time interaction (p=0.112). There were main effects of time (p<0.05) and trial (p=0.006), as 155 
well as an interaction effect (p=0.005) during the performance task. Higher values were recorded from 156 
20 to 30 min during the caffeine trial compared with placebo (p<0.05; Figure 2A). Pre-exercise skin 157 
temperature was similar between trials (p=0.429; Figure 2B). There was a main effect of time during 158 
the initial 60 min of exercise (p<0.05), but no main effect of trial (p=0.577) or trial x time interaction 159 
(p=0.116). Similarly, during the performance task there was a main effect of time (p<0.05), but no 160 
main effect of trial (p=0.970) or interaction effect (p=0.311; Figure 2B). 161 
Heart rate (Figure 2C), RPE (Figure 2D), and perceived thermal stress (Figure 2E) all increased 162 
throughout the initial 60 min of exercise (all p<0.05). There was also a main effect of trial for RPE 163 
(p=0.033), but there were no other trial (p>0.644) or interaction effects (p>0.253) for these variables. 164 
During the performance task heart rate showed main effects of time (p<0.05) and trial (p=0.011), but 165 
no interaction effect (p=0.904; Figure 2C).  166 
Caffeine concentrations remained below the limit of quantification during the placebo trial and for the 167 
baseline sample during the caffeine trial, increasing to 33.0 ± 5.7, 35.3 ± 10.9, and 32.6 ± 8.1 μM at 168 
60, 120 and 150 min post-capsule ingestion, respectively.  169 
Serum cortisol and prolactin both showed main effects of time (p<0.05), but no main effects of trial 170 
(p>0.572) or interaction effects (p>0.148; Table 1). Similarly, plasma glucose and the percentage 171 
change to blood and plasma volumes all showed main effects of time (p<0.05), but no main effects of 172 
trial (p>0.056) or trial x time interactions (p>0.111) occurred (Table 1).  173 
There were no main effects of time (p>0.363), trial (p>0.454) or interaction effects (p>0.410) for fat 174 
and carbohydrate oxidation and RER. Oxygen uptake showed a main effect of time (p=0.001), but no 175 
main effect of trial (p=0.361) or interaction effect (p=0.188). Over the entire 90 min of exercise, 176 
estimated sweat rates were higher in the caffeine trial (2.31 ± 0.43 L) than placebo (2.20 ± 0.37 L; 177 
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p=0.036). Accordingly, percentage body mass loss after exercise was greater during the caffeine trial 178 
(2.30 ± 0.36) than placebo (2.16 ± 0.31; p=0.029).   179 
 180 
Discussion 181 
This study investigated the performance and thermoregulatory effects of a 6 mg·kg−1 caffeine dose 182 
during prolonged exercise in the heat. This caffeine dose consistently improves endurance 183 
performance in temperate environmental conditions,2 yet there are conflicting reports when exercise is 184 
performed in the heat.5,3 In the study by Roelands et al. (2011),5 a 6 mg·kg−1 caffeine dose 185 
administered 60 min before exercise failed to enhance time-trial performance but increased core 186 
temperature during exercise in 30oC. Conversely, Ganio et al (2011)3 reported enhanced work 187 
production during a 15 min cycle performance task with no difference in core temperature 188 
between trials when 3 mg·kg−1 caffeine was ingested 60 min before and 45 min during exercise in 189 
33oC. The results of the present study agree with the latter findings, as caffeine provided a small, but 190 
significant ergogenic effect (Figure 1), with no difference in core or skin temperature between trials 191 
(Figure 2A and B).  192 
Several studies report no performance benefit in the heat after caffeine ingestion,5,6,7 attributing this 193 
response to an elevation in core temperature during exercise.5 However, even large caffeine doses (9 194 
mg·kg−1) result in only mild thermogenic effects,6,11 which is typically undetected by participants.11 In 195 
addition, five days of controlled caffeine intake (3 and 6 mg·kg−1) did not influence the core 196 
temperature response during exercise in 37oC.19 Alternatively, some researchers suggest that a high 197 
environmental temperature might negate the efficacy of caffeine.6 These authors reported no 198 
performance benefit in 40oC after ingestion of 9 mg·kg−1 caffeine. The lower environmental 199 
temperature and/or caffeine dose employed in the present study might account for these divergent 200 
findings. Additionally, 21 km race time in hot and humid conditions was not influenced by caffeine 201 
intakes of 5 or 9 mg·kg−1.7 However, participants in this study became ~4% dehydrated during 202 
exercise, thus it is unknown if caffeine would have enhanced performance if fluid-balance was 203 
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maintained. When hydration status is controlled across cool (12oC) and warm (33oC) environmental 204 
conditions, caffeine still improves endurance cycle performance.3  205 
The ergogenic effect of caffeine was attributed to changes in fat metabolism during exercise, resulting 206 
in a glycogen sparring effect.20 However, there is compelling evidence caffeine enhances performance 207 
through direct actions within the central nervous system.21 Caffeine increases synaptic dopamine 208 
concentrations in exercising rats, although large doses (10-30 mg·kg−1) are required to induce this 209 
response.22 Using positron emission topography, a moderate caffeine dose (300 mg) did not influence 210 
in vivo dopamine release in the human brain.23 Attenuated prolactin concentrations would suggest an 211 
increase in dopamine,24 but similar values were observed across trials (Table 1). Alternatively, 212 
caffeine influences key neuronal signaling proteins which mediate increases in physical activity and 213 
potentiates adenosine-dopamine receptor binding in striatum.25,26 A reduced perception of effort is a 214 
common response to caffeine intake, which might account for approximately 29% of its ergogenic 215 
effect.27 Participants in the present study reported lower RPE values during the initial hour of exercise 216 
with caffeine (Figure 2D), which is likely mediated by a reduced activity of cortical premotor and 217 
motor areas.28  218 
Previous reports demonstrated that 6 mg·kg−1 caffeine enhanced sweat-electrolyte losses in 36oC,12 219 
while 3 mg·kg−1 augmented sweat rates during submaximal cycle exercise in 24oC.29 In the present 220 
study, higher sweat rates were observed during the caffeine trial than placebo over the entire 90 min 221 
of exercise (2.31 ± 0.43 L vs. 2.20 ± 0.37 L; p=0.036). This small difference likely reflects the higher 222 
work rate during the performance task in the caffeine trial and the concomitant elevation in core 223 
temperature (Figure 2A). During prolonged exercise at a fixed work-rate, caffeine did not adversely 224 
influence fluid-balance, sweat rate or serum osmolality in cool (12oC) and warm (33oC) 225 
environmental conditions compared with placebo.3 Additionally, there were no differences in fluid, 226 
electrolyte, or renal indices of hydration after 5 days of controlled caffeine intake (3 and 6 mg·kg−1) 227 
versus placebo.30  228 
 229 
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Conclusion 230 
In conclusion, supplementation with 6 mg·kg−1 caffeine 60 min before prolonged exercise in 30oC and 231 
50% RH improved endurance cycle performance in non-heat acclimated participants, without any 232 
measureable change to thermoregulation versus placebo. There appeared to be a developing trend for 233 
core temperature during the initial 60 min of exercise (interaction effect, P=0.112), suggesting that a 234 
longer period of fixed-intensity might enable caffeine to elicit a greater increase in core temperature 235 
than placebo under these environmental conditions. However, the difference at the end of the preload 236 
was small (0.03oC, Figure 2A), which was also undetected by participants (Figure 4B). These data, 237 
together with previous reports,3 suggest that moderate caffeine doses which typically improve 238 
endurance performance in temperate environmental conditions,2 also benefit endurance cycle 239 
performance in the heat.  240 
 241 
 242 
Practical applications 243 
• Moderate caffeine doses appear to be ergogenic to endurance cycle performance for 244 
recreationally active, non-heat acclimated, fasted individuals competing in the heat. 245 
• Supplementation with 6 mg·kg−1 caffeine does not significantly influence core or skin 246 
temperature up to 60 min of cycle exercise at a fixed work-rate. 247 
• During prolonged fixed-intensity exercise in the heat, moderate caffeine intakes attenuate 248 
perceived exertion compared with placebo. 249 
 250 
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Table 1 Circulating concentrations of cortisol, prolactin and glucose and the percentage change to 
blood and plasma volumes during the experimental trials. 
 Treatment -60 0 60 90 
Cortisol (nM) 
 
Prolactin (mIU·L−1) 
 
Glucose (mmol·mL−1) 
 
Blood volume (%) 
 
Plasma volume (%) 
 
placebo 
caffeine 
placebo 
caffeine 
placebo 
caffeine 
placebo 
caffeine 
placebo 
caffeine 
449.1 ± 127.6 
450.4 ± 140.7 
182.7 ± 73.1 
160.7 ± 38.9 
4.33 ± 0.35 
4.34 ± 0.38 
0.0 ± 0.0 
0.0 ± 0.0  
0.0 ± 0.0 
0.0 ± 0.0 
483.7 ± 115.3 
458.4 ± 137.6 
152.8 ± 30.6 
146.6 ± 36.7 
4.23 ± 0.39* 
4.25 ± 0.38* 
0.19 ± 0.56 
0.13 ± 0.67 
0.20 ± 1.42 
0.02 ± 1.34 
519.4 ± 105.5 
524.3 ± 135.0 
405.8 ± 61.8* 
380.3 ± 71.1* 
4.88 ± 0.36* 
4.88 ± 0.37* 
-1.67 ± 0.99* 
-2.02 ± 0.95* 
-3.29 ± 1.83* 
-3.88 ± 1.69* 
701.1 ± 130.4* 
734.8 ± 142.6* 
534.2 ± 105.6* 
529.8 ± 126.7* 
6.06 ± 0.17* 
6.17 ± 0.16* 
-4.87 ± 2.45* 
-5.49 ± 1.95* 
-8.25 ± 2.67* 
-9.20 ± 2.67* 
Values are mean ± SD. *significant difference (P<0.05) from -60.  
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Figure Captions 338 
Figure 1: Total kJ produced (bars) and individual responses (lines) during the experimental trials. 339 
Figure 2: Core temperature (a), skin temperature (b), heart rate (c), RPE (d), and perceived thermal 340 
stress (e) during the experimental trials. *denotes a significant difference (P<0.05) between trials.  341 
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